APA (7th ed.) Citation

S, B., D, K., CC, C., S, C., A, C., A, O., . . . T, S. (2026). Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice. European journal of cancer (Oxford, England : 1990), 238, 116686. https://doi.org/10.1016/j.ejca.2026.116686

Chicago Style (17th ed.) Citation

S, Blocker, et al. "Risk Factors for CRS and ICANS with Tarlatamab in Small Cell Lung Cancer and Associated Efficacy Outcomes: Insights from Clinical Practice." European Journal of Cancer (Oxford, England : 1990) 238 (2026): 116686. https://doi.org/10.1016/j.ejca.2026.116686.

MLA (9th ed.) Citation

S, Blocker, et al. "Risk Factors for CRS and ICANS with Tarlatamab in Small Cell Lung Cancer and Associated Efficacy Outcomes: Insights from Clinical Practice." European Journal of Cancer (Oxford, England : 1990), vol. 238, 2026, p. 116686, https://doi.org/10.1016/j.ejca.2026.116686.